Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters

Jenna Scott was 29, seven months pregnant, and suddenly, feeling very sick.

July 02, 2026

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

I performed my first colonoscopy as a board-certified gastroenterologist more than 20 years ago, at a time when the procedure was firmly established as the “gold standard” for colorectal cancer screening.

July 02, 2026

Vol.52 No.26

By Paul J. Limburg

Trials & Tribulations

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Drugs & Targets

FDA approves Trodelvy for first-line treatment of mTNBC

FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.

July 02, 2026

Vol.52 No.26

Clinical Roundup

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Sigvotatug vedotin, an integrin beta-6 directed antibody-drug conjugate, did not show a statistically significant improvement in the primary endpoint of overall survival, compared to docetaxel, according to the results of the phase III SigVie-002 study (previously known as Be6A Lung-01).

June 26, 2026

Vol.52 No.25

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

YOU MAY BE INTERESTED IN

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

FDA approves Trodelvy for first-line treatment of mTNBC

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

YOU MAY BE INTERESTED IN

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers noteOne woman’s pregnancy shows how this distinction matters

Is it time to re-assess the practice and practicality of screening colonoscopy?Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancerNew guidelines offer another option

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

FDA approves Trodelvy for first-line treatment of mTNBC

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Never miss an issue!

Login

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option